BofA lowered the firm’s price target on Waystar (WAY) to $38 from $45 and keeps a Buy rating on the shares. The firm’s Q1 survey results indicate health systems looking to make a change to their current RCM strategy was unchanged quarter-over-quarter, reports the analyst, who cites peer multiple contraction for the firm’s lowered target.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WAY: